OHR Pharmaceutical Inc (NASDAQ:OHRP), saw Director Sherie June Almenoff increase her stake in the company. Almenoff purchased 3,200 shares at an average of $8.34 per share. TOHR Pharmaceutical Inc. (NASDAQ:OHRP) weekly performance is -16.58%. On last trading day company shares ended up $9.51. Analysts mean target price for the company is $34.00. OHR Pharmaceutical Inc. (NASDAQ:OHRP) distance from 50-day simple moving average (SMA50) is 6.57%.
Biota Pharmaceuticals Inc. (NASDAQ:BOTA) CEO Russell H. Plumb purchased 32,031 shares of Biota Pharmaceuticals stock in a transaction dated Wednesday, June 11th. The shares were purchased at an average price of $2.99 per share, for a total transaction of $95,772.69. Following the acquisition, the chief executive officer now directly owns 127,579 shares in the company, valued at approximately $381,461. Biota Pharmaceuticals Inc. (NASDAQ:BOTA) shares advanced 4.01% in last trading session and ended the day on $2.85. BOTA gross Margin is 29.50% and its return on assets is -8.00%.Biota Pharmaceuticals Inc. (NASDAQ:BOTA) quarterly performance is -53.36%.
Opko Health Inc. (NYSE:OPK) CEO Phillip Md Et Al Frost purchased 65,000 shares of Opko Health stock on the open market in a transaction that occurred on Wednesday, June 25th. The stock was purchased at an average cost of $8.65 per share, with a total value of $562,250.00. Following the acquisition, the chief executive officer now directly owns 1,987,500 shares in the company, valued at approximately $17,191,875. Opko Health Inc. (NYSE:OPK) shares moved down -2.86% in last trading session and was closed at $8.84, while trading in range of $8.82 – $9.09. Opko Health Inc. (NYSE:OPK) year to date (YTD) performance is 4.74%.
Omeros corporation (NASDAQ:OMER) Director Peter A. Md Demopulos bought 6,153 shares of the stock in a transaction dated Tuesday, June 24th. The shares were purchased at an average cost of $16.20 per share, with a total value of $99,678.60. Following the purchase, the director now directly owns 181,220 shares of the company’s stock, valued at approximately $2,935,764. Omeros Corporation (NASDAQ:OMER) ended the last trading day at $17.40. Company weekly volatility is calculated as 7.60% and price to cash ratio as 11.30.Omeros Corporation (NASDAQ:OMER) showed a positive weekly performance of 13.28%.
Merrimack Pharmaceuticals Inc. (NASDAQ:MACK) Director Gary L. Crocker bought 36,000 shares of Merrimack Pharmaceuticals stock on the open market in a transaction that occurred on Monday, June 23rd. The stock was purchased at an average cost of $6.84 per share, for a total transaction of $246,240.00. Merrimack Pharmaceuticals Inc. (NASDAQ:MACK) weekly performance is 7.68%. On last trading day company shares ended up $7.29. Analysts mean target price for the company is $13.40. Merrimack Pharmaceuticals Inc. (NASDAQ:MACK) distance from 50-day simple moving average (SMA50) is 7.15%.